Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update

Entera Bio Ltd. (NASDAQ:ENTX) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 44,200 shares, a growth of 9.4% from the October 15th total of 40,400 shares. Based on an average daily volume of 31,500 shares, the short-interest ratio is currently 1.4 days.

Entera Bio Stock Down 4.0 %

Shares of Entera Bio stock opened at $1.66 on Tuesday. The firm’s 50 day moving average price is $1.85 and its 200-day moving average price is $1.91. Entera Bio has a 52-week low of $0.52 and a 52-week high of $3.35. The company has a market cap of $59.40 million, a P/E ratio of -6.38 and a beta of 1.58.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Entera Bio in a research report on Monday, November 11th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Parkman Healthcare Partners LLC grew its position in shares of Entera Bio by 2.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock worth $781,000 after buying an additional 9,558 shares during the last quarter. Signature Estate & Investment Advisors LLC purchased a new position in shares of Entera Bio in the 3rd quarter worth approximately $90,000. Finally, Virtu Financial LLC purchased a new position in shares of Entera Bio in the 1st quarter worth approximately $37,000. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.